ReviewCancers2015
Revealing the Complexity of Breast Cancer by Next Generation Sequencing.
Review in Cancers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Applying whole-genome and whole-exome sequencing in breast cancer: a review of the landscape.Breast cancer (Tokyo, Japan) · 2024Review
- Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer.Cancer medicine · 2024Article
- Long-term oncologic outcomes following breast cancer surgery in adolescents and young adults: a single-center retrospective analysis.Frontiers in oncology · 2024Article
- Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating Transcripts.International journal of molecular sciences · 2022Article
- Article
- Deciphering molecular mechanisms of metastasis: novel insights into targets and therapeutics.Cellular oncology (Dordrecht, Netherlands) · 2021Review
- High Expression of CEMIP Correlates Poor Prognosis and the Tumur Microenvironment in Breast Cancer as a Promisingly Prognostic Biomarker.Frontiers in genetics · 2021Article
- Article
- Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.Molecular carcinogenesis · 2019Article
- Cancer biomarker discovery and translation: proteomics and beyond.Expert review of proteomics · 2019Article
- Molecular Subtypes of Indonesian Breast Carcinomas - Lack of Association with Patient Age and Tumor SizeAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Identification of novel genetic loci GAL3ST4 and CHGB involved in susceptibility to leprosy.Scientific reports · 2017Article
- Recent Advances in Comprehending the Signaling Pathways Involved in the Progression of Breast Cancer.International journal of molecular sciences · 2017Review
- Breast cancer in young women: an overview.Updates in surgery · 2017Review
- Copy Number Profiling of MammaPrint™ Genes Reveals Association with the Prognosis of Breast Cancer Patients.Journal of breast cancer · 2017Article
- Suppressing role of miR-520a-3p in breast cancer through CCND1 and CD44.American journal of translational research · 2017Article
- Progress in the clinical detection of heterogeneity in breast cancer.Cancer medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last few years the increasing usage of "-omic" platforms, supported by next-generation sequencing, in the analysis of breast cancer samples has tremendously advanced our understanding of the disease. New driver and passenger mutations, rare chromosomal rearrangements and other genomic aberrations identified by whole genome and exome sequencing are providing missing pieces of the genomic architecture of breast cancer. High resolution maps of breast cancer methylomes and sequencing of the miRNA microworld are beginning to paint the epigenomic landscape of the disease. Transcriptomic profiling is giving us a glimpse into the gene regulatory networks that govern the fate of the breast cancer cell. At the same time, integrative analysis of sequencing data confirms an extensive intertumor and intratumor heterogeneity and plasticity in breast cancer arguing for a new approach to the problem. In this review, we report on the latest findings on the molecular characterization of breast cancer using NGS technologies, and we discuss their potential implications for the improvement of existing therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.